CPT code 81256 – HFE gene analysis for hereditary hemochromatosis

Key takeaways

CPT code 81256 reports HFE common-variant analysis (C282Y, H63D, S65C) for hereditary hemochromatosis, not full HFE gene sequencing.

It is a Tier 1 molecular pathology code in the 81105-81383 range, paid under the CMS Clinical Laboratory Fee Schedule.

E83.110 (hereditary hemochromatosis) is the primary ICD-10-CM pairing. Z13.88 is the wrong code altogether, because it describes screening for contaminant exposure.

The correct screening code is Z13.228, but most payers still deny a screen-only claim without a documented clinical indication.

The performing lab bills 81256 by default. The ordering practice appends modifier 90 only where the payer allows it to bill reference-lab work.

CPT code 81256: Official descriptor and test overview

CPT code 81256 is defined by the American Medical Association (AMA) as HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C282Y, H63D). It covers variant-specific genotyping of the HFE gene, the main genetic cause of hereditary hemochromatosis. The lab that performs the test bills it under the Clinical Laboratory Fee Schedule.

The code does not cover sequencing of the whole gene. Full HFE sequencing billed as 81256 is a coding mismatch that will generate a denial, so report it with 81479 instead.

The HFE gene on chromosome 6 encodes a protein that regulates iron absorption. Pathogenic variants in this gene cause the body to absorb more iron than it needs, leading to progressive organ damage if untreated. Three variants are most clinically relevant for testing purposes.

Molecular pathology tier classification

CPT code 81256 is a Tier 1 molecular pathology code. Tier 1 codes (81105-81383) are gene-specific. Each one names a single gene and the analysis performed on it, so 81256 always means HFE common-variant testing. Laboratories are paid for it under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule (PFS).

Tier 2 codes (81400-81408) cover less common gene analyses that have no code of their own. They are grouped into nine levels, Level 1 to Level 9, graded by the technical resources and interpretive work the test demands. The number of variants tested does not set the level, and 81256 does not appear on any Tier 2 list.

Older guidance sometimes describes HFE testing with molecular “stacking” codes (83890-83914). Those codes were deleted in 2013. Bill HFE common-variant analysis as one unit of 81256, never as a Tier 2 level or a stack of method codes.

ICD-10 codes to pair with 81256

Selecting the correct ICD-10-CM diagnosis code is the single most preventable source of 81256 claim denials. The pairing must reflect the clinical reason for ordering the test, not a generic screen.

Payers cross-reference the submitted diagnosis code against their covered-indications list before adjudicating the claim. Medicare does this through Local Coverage Determinations issued by contractors such as CGS Medicare.

Z13.88 is the most common coding mistake on 81256 claims. It covers screening for disorders caused by contaminant exposure, so it never supports an HFE test. The screening code for this test is Z13.228, but that fixes only the code. Most payers, Medicare included, do not cover hereditary hemochromatosis genetic testing for screening alone.

The chart note must document a clinical indication. That means elevated transferrin saturation, elevated serum ferritin, or a first-degree relative with a confirmed HFE pathogenic variant.

81256 vs. related genetic analysis codes

Coders frequently confuse CPT 81256 with adjacent molecular pathology codes when panels or multiple gene tests are ordered at the same encounter. The table below separates the most commonly compared codes.

81255 and 81256 are both Tier 1 codes with adjacent numbers, which generates lookup errors. Verifying the gene name in the lab requisition before coding prevents this mismatch. When both tests are ordered at the same encounter for different clinical indications, they may be billed together with appropriate ICD-10 linkage for each.

Medicare reimbursement rates

CPT code 81256 is priced under the CMS Clinical Laboratory Fee Schedule rather than the Physician Fee Schedule. This matters because the CLFS is updated annually through a separate rulemaking process from the PFS. The performing laboratory bills directly to Medicare using their own NPI and billing entity.

CLFS rates for molecular pathology codes are adjusted every year, so a figure copied from last year’s schedule goes stale fast. Check the current calendar-year rate in the CMS CLFS download file or FastRVU’s 2026 RVU lookup before you submit claims.

CLFS rates for molecular pathology codes have been subject to multi-year phase-in reductions under the PAMA (Protecting Access to Medicare Act) framework. The rate for any given year may be lower than the prior year. Coders should pull the current CLFS file from cms.gov each January rather than relying on cached fee schedule data.

Medicare coverage requirements for CPT 81256

Medicare covers CPT code 81256 when specific clinical criteria are met, as documented in Local Coverage Determinations issued by Medicare Administrative Contractors. CGS Medicare covers a multi-state jurisdiction. It requires the ordering provider to document at least one of the following in the chart note before the test is ordered.

• Transferrin saturation greater than 45% on at least two separate measurements
• Serum ferritin persistently elevated above the normal range with no alternative explanation
• Symptomatic iron overload with documented hepatic, cardiac, or endocrine involvement
• First-degree family member with a confirmed pathogenic HFE variant (C282Y homozygous or C282Y/H63D compound heterozygous)

Medicare does not cover 81256 for population-based screening in asymptomatic individuals without the above clinical indicators. A Medicare claim carrying only a screening code, whether the wrong Z13.88 or the correct Z13.228, is a near-certain denial. The chart note must reflect the clinical rationale in language that maps directly to LCD-covered indications.

Flag the tests that need LCD-based documentation at the point of order, not at billing. That habit prevents downstream denials that need costly appeals.

Prior authorization requirements by payer

Prior authorization requirements for CPT code 81256 vary significantly by payer. Medicare itself does not require prior authorization, but its LCD criteria function as a de facto clinical documentation gate. Commercial payers increasingly route genetic testing through managed care organizations for authorization review.

Verify the patient’s insurance eligibility before ordering, then request authorization straight after. A claim for a test that required PA but did not have one is a denial that cannot be appealed on clinical grounds alone.

eviCore’s MOL.TS.183.A guideline governs HFE genetic testing authorization for many BCBS and commercial plan members. A PA request that cites the guideline number and attaches the iron studies typically moves through review faster. A clinical narrative alone tends to stall.

Approvals typically expire 90 to 180 days after issue, so check the validity window on the payer portal. Record the expiration date alongside the order so the claim goes out while the approval still stands.

Top denial reasons for CPT 81256 claims

CPT code 81256 denials are almost always preventable. The most common triggers fall into six categories, each with a specific corrective action.

1. Non-covered or missing ICD-10 pairing. Z13.88 describes contaminant exposure, so it triggers automatic denial on an HFE claim. Z13.228 is the correct screening code, but most payers deny it as the sole code too. Fix: use E83.110 or E83.118 with supporting clinical documentation in the chart note. Check the LCD’s covered-code list before submission.
2. Prior authorization not obtained. For commercial plans routed through eviCore, submitting without a valid PA number is a hard denial. The claim can be resubmitted after obtaining PA. Payers generally refuse retrospective authorization unless the test was medically urgent and PA could not be obtained in advance. Fix: build a PA check into the order workflow, not the billing workflow.
3. Duplicate test submitted. 81256 covers C282Y, H63D, and S65C in a single code. Submitting 81256 twice for the same patient in the same benefit period (once for C282Y, once for H63D) is a duplicate claim. Fix: confirm the lab is not unbundling individual variants across multiple requisitions.
4. Wrong place of service. Reference laboratory claims should use POS 81 (independent laboratory). Submitting under POS 11 (office) when the performing entity is a reference lab generates an edit. Fix: confirm which entity performed the test and bills it, then assign POS accordingly.
5. Insufficient medical necessity documentation. A claim may pass the ICD-10 check and still be denied on post-payment audit if the chart note does not document the clinical rationale. Fix: make sure the chart note records the iron study values, their dates, and the ordering provider’s clinical reasoning, not just a diagnosis code.
6. Billing 81256 for a different test. If full HFE sequencing was performed rather than common variant analysis, 81256 understates the service. Use 81479 (unlisted molecular pathology) in that scenario, with an attached report. Fix: compare the lab report against the charge during charge capture, before the claim goes out.

Reviewing electronic remittance advice at the claim level, not just the batch summary, gives billing staff the CARC and RARC codes. Those codes identify which of these triggers caused each denial. Our guide to denial codes explains what each one means and which appeal path it calls for.

Documentation checklist for medical necessity

The chart note is the primary defense in a 81256 claim audit. Payers that conduct retrospective medical necessity reviews look for specific data points. When these elements are absent, the claim is vulnerable regardless of whether it was paid initially.

• Iron studies with dates and values. Transferrin saturation percentage and serum ferritin level from at least one laboratory result, with the collection date. Two separate elevated results strengthen the record.
• Clinical symptoms or organ involvement. Any documented fatigue, joint pain, liver enzyme elevation, or cardiac findings that prompted the workup. Generic “rule out hemochromatosis” language without supporting data is insufficient.
• Family history notation. If the indication is a positive family history, record the relationship to the affected individual. Also record the variant confirmed in that relative (for example, “mother confirmed C282Y homozygous”).
• Ordering provider attestation. The chart note should include the provider’s clinical reasoning for ordering the HFE gene analysis specifically, not just a general reference to iron studies.
• Test requisition copy. Retain the lab requisition in the record, specifying which variants were ordered. This prevents disputes about whether 81256 (common variants) or a more comprehensive analysis was intended.
• Payer-specific forms. Some commercial plans require a genetic testing request form. Check the payer’s provider portal for plan-specific documentation requirements before submitting.

Build this checklist into a standardized order template. The documentation then exists at the time of ordering instead of being reconstructed at audit time. A digital order form with required fields stops an order from going out until the iron studies and indication are recorded.

Place of service and modifier guidance

Place of service and modifier choices on CPT code 81256 claims depend on which entity performed the test. They also depend on whether the circumstances need extra billing context. A wrong combination generates automated edits that delay payment, even when the ICD-10 code and prior authorization are correct.

The CLIA certification requirement applies to in-house physician office laboratories. A practice that collects the specimen and sends it to Quest or LabCorp is the ordering entity, not the performing entity. By default it does not bill 81256. The reference lab bills using POS 81, and the practice bills only for the office visit.

Modifier 90 is the one exception. Some commercial payers let the ordering provider bill for reference-lab work, but many Medicare contractors don’t permit it. Get the payer’s approval in writing before you bill that way. The decision below shows which entity bills in each case.

Claims management software can assign the POS from the performing-entity field on the lab order, which cuts manual selection errors. Capture POS codes and modifiers on the superbill at the time of service rather than reconstructing them at billing.

How Pabau keeps CPT 81256 claims documented and paid

HFE testing splits billing across two entities. The ordering practice records the iron studies, family history and clinical reasoning. The reference lab then bills 81256 against that record, so a thin chart note at the practice turns into a denial at the lab.

Practice management software like Pabau captures that documentation at the point of order, before the specimen leaves the office. It checks patient eligibility in real time and submits claims through its Claim.MD clearinghouse integration. ERA remittances post back against the original charge, so a denied or underpaid claim surfaces without a separate reconciliation step.

Streamline your lab billing workflow

Pabau connects ordering practices with the Claim.MD clearinghouse for electronic submission, real-time eligibility checks, and ERA processing. CPT code 81256 claims move from lab requisition to paid claim without manual re-entry.

Book a demo

Conclusion

Treat 81256 as an order-stage decision. By the time the claim reaches billing, the diagnosis, the authorization and the performing entity are already fixed. A coder can only report what the chart and the requisition show.

So the work that pays off sits with the ordering provider. Document the iron studies or family history, and pair E83.110 or another covered diagnosis rather than a screening code. Then let the performing lab bill unless the payer has approved modifier 90.

The trade-off is a few extra minutes at the order against an appeal you may not win. To see how Pabau captures lab-order documentation and submits the claim in one workflow, book a demo.

Continue your research

Need to understand how claim submissions reach payers? Medical claims clearinghouse explained covers how clearinghouses validate, route, and track electronic claims before adjudication.

Want to see how your CPT and ICD-10 codes travel to the payer? 837 file format guide explains the transaction structure that carries your claim data.

Fighting denials on lab claims? Denial management in healthcare sets out a workflow for tracking, appealing, and preventing repeat denials.

Want fewer claims bounced at the first edit? What makes a clean claim lists the fields and checks a claim needs to pass first time.

Managing credentialing for the providers who order genetic tests? Credentialing with insurance companies walks through the enrollment steps required before claims can be processed.

Frequently asked questions